SB641
Office-based buprenorphine treatment; Board of Medicine to amend regulations.
Status:
In Senate
Latest Action:
Feb. 5, 2026
Senate: Reported from Education and Health (14-Y 0-N)
Chief Patron:
Todd Pillion (R)
Session:
2026 Regular Session
Summary
As Introduced. Board of Medicine;
office-based buprenorphine treatment; counseling. Directs the Board of Medicine to amend its regulations regarding office-based buprenorphine treatment to require providers to offer counseling or referral to counseling to each patient as clinically necessary and mutually agreed-upon. The bill specifies that a patient's refusal of counseling does not preclude the patient ... (More) from receiving office-based buprenorphine treatment for opioid use disorder. This bill is a recommendation of the Joint Commission on Health Care. (Less)-
Bill History
- 01/14/2026 - Senate: Prefiled and ordered printed; Offered 01-14-2026 26104754D
- 01/14/2026 - Senate: Referred to Committee on Education and Health
- 01/21/2026 - Senate: Fiscal Impact Statement from Department of Planning and Budget (SB641)
- 01/30/2026 - Senate: Assigned Education sub: Health Professions
- 02/05/2026 - Senate: Reported from Education and Health (14-Y 0-N)
